RUNX2 and breast cancer: Additionally, studies on triple-negative breast cancer have confirmed that RUNX2 increases TGF-β-mediated regulation of CD44+/CD24- breast cancer stem cells, leading to increased cancer stemness, EMT, and apoptosis resistance, as well as conferring resistance to epirubicin 43.